Nimodipine-associated standard dose reductions and neurologic outcomes after aneurysmal subarachnoid hemorrhage: the era of pharmacogenomics
The Pharmacogenomics Journal · 2024
DOI: 10.1038/s41397-024-00340-3 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Pharmacogenomics Journal, 2024. Verfasst von Adriana Vázquez-Medina und 11 weiteren Autor:innen. Beteiligte Einrichtung: University of Puerto Rico, Medical Sciences Campus School of Medicine, San Juan, Puerto Rico. Hauptthemen laut MEDLINE: Nimodipine, Subarachnoid Hemorrhage, Calcium Channel Blockers, Pharmacogenetics. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 31 Literaturangaben.
Abstract (Originalsprache)
Nimodipine, an L-type cerebroselective calcium channel antagonist, is the only drug approved by the US Food and Drug Administration for the neuroprotection of patients with aneurysmal subarachnoid hemorrhage (aSAH). Four randomized, placebo-controlled trials of nimodipine demonstrated clinical improvement over placebo; however, these occurred before precision medicine with pharmacogenomics was readily available. The standard enteral dose of nimodipine recommended after aSAH is 60 mg every 4 h. However, up to 78% of patients with aSAH develop systemic arterial hypotension after taking the drug at the recommended dose, which could theoretically limit its neuroprotective role and worsen cerebral perfusion pressure and cerebral blood flow, particularly when concomitant vasospasm is present. We investigated the association between nimodipine dose changes and clinical outcomes in a consecutive series of 150 patients (mean age, 56 years; 70.7% women) with acute aSAH. We describe the pharmacogenomic relationship of nimodipine dose reduction with clinical outcomes. These results have major implications for future individualized dosing of nimodipine in the era of precision medicine.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- University of Puerto Rico, Medical Sciences Campus School of Medicine, San Juan, Puerto Rico.
- Department of Neurology, Mayo Clinic, Jacksonville, FL, USA.
- Department of Emergency Medicine, Mayo Clinic, Jacksonville, FL, USA.
- Division of Hospital Internal Medicine, Mayo Clinic, Jacksonville, FL, USA.
- Division of Clinical Trials and Biostatistics, Mayo Clinic, Jacksonville, FL, USA.
- Department of Artificial Intelligence and Informatics, Mayo Clinic, Jacksonville, FL, USA.
ORCID-Profile: Courtney L James, Rickey E Carter, Owen A Ross, Aixa De Jesús Espinosa, W David Freeman
Zitieren
APA
Vázquez-Medina, A., Turnbull, M. T., James, C. L., Cowart, J. B., Lesser, E., Carter, R. E., Ross, O. A., Miller, D. A., Meschia, J. F., De Jesús Espinosa, A., Weinshilboum, R., & Freeman, W. D. (2024). Nimodipine-associated standard dose reductions and neurologic outcomes after aneurysmal subarachnoid hemorrhage: the era of pharmacogenomics. The Pharmacogenomics Journal. https://doi.org/10.1038/s41397-024-00340-3
Vancouver
Vázquez-Medina A, Turnbull MT, James CL, Cowart JB, Lesser E, Carter RE, et al. Nimodipine-associated standard dose reductions and neurologic outcomes after aneurysmal subarachnoid hemorrhage: the era of pharmacogenomics. The Pharmacogenomics Journal. 2024. doi:10.1038/s41397-024-00340-3
BibTeX
@article{VzquezMedina2024,
author = {Vázquez-Medina, Adriana and Turnbull, Marion T and James, Courtney L and Cowart, Jennifer B and Lesser, Elizabeth and Carter, Rickey E and Ross, Owen A and Miller, David A and Meschia, James F and De Jesús Espinosa, Aixa and Weinshilboum, Richard and Freeman, W David},
title = {Nimodipine-associated standard dose reductions and neurologic outcomes after aneurysmal subarachnoid hemorrhage: the era of pharmacogenomics},
journal = {The Pharmacogenomics Journal},
year = {2024},
doi = {10.1038/s41397-024-00340-3}
}
EUVIMED